Hepatocyte Growth Factor-Pipeline Review H2 2017

According to the recently published report 'Hepatocyte Growth Factor-Pipeline Review, H2 2017'; Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) pipeline Target constitutes close to 13 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes.

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)-Hepatocyte growth factor (HGF) is a paracrine cellular growth and morphogenic factor secreted by mesenchymal cells and stimulates epithelial cell proliferation, motility, morphogenesis and angiogenesis in various organs via tyrosine phosphorylation of its receptor. It has a major role in embryonic organ development, specifically in myogenesis, in adult organ regeneration and in wound healing. In addition, HGF exerts protective effects on epithelial and non-epithelial organs (including the heart and brain) via anti-apoptotic and anti-inflammatory signals.

The report 'Hepatocyte Growth Factor-Pipeline Review, H2 2017' outlays comprehensive information on the Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

Request Sample Report@ http://www.reportsweb.com/inquiry&RW00011060478/sample

It also reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1, 5 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System, Hematological Disorders, Immunology and Metabolic Disorders which include indications Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Critical Limb Ischemia, Non-Small Cell Lung Cancer, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), Angina (Angina Pectoris), Arteriosclerosis, Chronic Heart Failure, Colorectal Cancer, Dementia, Diabetic Ischemic Foot Ulcers, Diabetic Peripheral Neuropathy, Gastric Cancer, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Kidney Cancer (Renal Cell Cancer), Leiomyosarcoma, Liver Cancer, Lymphedema, Metastatic Cancer, Multiple Myeloma (Kahler Disease), Myocardial Infarction, Myocardial Ischemia, Parkinson's Disease, Rheumatoid Arthritis, Solid Tumor and Thromboangiitis obliterans (Buerger disease).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)-Overview 7
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)-Therapeutics Development 8
Products under Development by Stage of Development 8
Products under Development by Therapy Area 9
Products under Development by Indication 10
Products under Development by Companies 13
Products under Development by Universities/Institutes 17
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)-Therapeutics Assessment 19
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 23

Inquiry for Buying@ http://www.reportsweb.com/inquiry&RW00011060478/buying

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)-Companies Involved in Therapeutics Development 25
AnGes MG Inc 25
F-star Biotechnology Ltd 25
Kringle Pharma Inc 26
M3 Biotechnology Inc 26
Minerva Biotechnologies Corp 26
Molecular Partners AG 27
ViroMed Co Ltd 27
Yooyoung Pharm Co Ltd 28
Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)-Drug Profiles 30
beperminogene perplasmid-Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
FS-101-Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Gene Therapy to Activate HGF for Myocardial Infarction-Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Gene Therapy to Antagonize HGF for Rheumatoid Arthritis and Hepatocellular Carcinoma-Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37

Find More Information@ http://www.reportsweb.com/hepatocyte-growth-factor-pipeline-review-h2-2017

List of Figures
Number of Products under Development by Stage of Development, H2 2017 8
Number of Products under Development by Therapy Areas, H2 2017 9
Number of Products under Development by Top 10 Indications, H2 2017 10
Number of Products by Mechanism of Actions, H2 2017 19
Number of Products by Stage and Mechanism of Actions, H2 2017 19
Number of Products by Routes of Administration, H2 2017 21
Number of Products by Stage and Routes of Administration, H2 2017 21
Number of Products by Molecule Types, H2 2017 23
Number of Products by Stage and Molecule Types, H2 2017 23

About ReportsWeb:
ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

Contact Us:
Call: +1-646-491-9876
Email: sales@reportsweb.com

This release was published on openPR.